COHANCE LIFESCIENCES LIMITED (formerly known as Suven Pharmaceuticals Limited) — Quarter ended 31 March 2026 and year ended 31 March 2026
The document includes audited standalone and consolidated financial results for the quarter ended 31 March 2026 and the year ended 31 March 2026, along with Statement of Assets and Liabilities and Cash Flow Statements.
| Sl. No. | PARTICULARS | For the quarter ended | For the year ended |
|---|---|---|---|
| 31 March 2026 (Unaudited) | 31 December 2025 (Unaudited) | ||
| 1 | Income | ||
| Revenue from operations | 567.55 | 481.58 | |
| Other income | (0.79) | 6.12 | |
| Total income | 566.76 | 487.70 | |
| 2 | Expenses | ||
| a) Cost of materials consumed | 134.63 | 193.29 | |
| b) Changes in inventories of finished goods and work-in-progress | 76.76 | (36.36) | |
| c) Employee benefits expense | 96.81 | 85.09 | |
| d) Finance costs | 5.17 | 5.25 | |
| e) Depreciation and amortisation expenses | 37.66 | 33.36 | |
| f) Other expenses | 142.78 | 136.78 | |
| Total expenses | 493.81 | 417.41 | |
| 3 | Profit before exceptional items & tax (1-2) | 72.95 | 70.29 |
| 4 | Exceptional items (refer note 6) | 16.51 | 4.86 |
| 5 | Profit before tax (3-4) | 56.44 | 65.43 |
| 6 | Tax expenses | ||
| a) Current tax | 16.39 | 12.66 | |
| b) Current tax – earlier years | 4.69 | ||
| c) Deferred tax | 0.80 | 5.48 | |
| Total tax expense (net) | 21.88 | 18.14 | |
| 7 | Net profit for the period/year (5-6) | 34.56 | 47.29 |
| 8 | Other comprehensive income / (loss) | ||
| 8.a | Items that will not be reclassified to profit or loss | ||
| (i) | Gain / (loss) on remeasurement of defined benefit plan | 2.20 | (0.21) |
| (ii) | Income tax relating to items that will not be reclassified to profit or loss | (0.56) | 0.06 |
| 8.b | Items that will be reclassified to profit or loss | ||
| (i) | Effective portion of gain / (loss) on hedging instrument in a cash flow hedging | (5.54) | 4.25 |
| (ii) | Income tax relating to items that will be reclassified to profit or loss | 1.40 | (1.08) |
| Total other comprehensive income/(loss) for the period/year | (2.50) | 3.02 | |
| 9 | Total comprehensive income for the period/year (7+8) | 32.06 | 50.31 |
| 10 | Paid-up equity share capital (refer note 4) | 38.26 | 38.26 |
| Face Value of the Share | ₹1.00 | ₹1.00 | |
| 11 | Other equity | ||
| 12 | Earning Per Share (EPS) – Face value of ₹1/- each (refer note 8) | ||
| a) Basic | 0.90 (not annualised) | 1.24 (not annualised) | |
| b) Diluted | 0.90 (not annualised) | 1.24 (not annualised) |
| Sl. No. | PARTICULARS | 31 March 2026 Unaudited (refer note 9) |
31 December 2025 Unaudited |
31 March 2025 Unaudited Restated (refer note 4 & 9) |
31 March 2026 Audited |
31 March 2025 Audited Restated (refer note 4) |
|---|---|---|---|---|---|---|
| 1 | Income | |||||
| Revenue from operations | 619.12 | 544.55 | 840.42 | 2,268.55 | 2,608.50 | |
| Other income | (1.84) | 6.16 | 12.05 | 34.09 | 69.21 | |
| Total income | 617.28 | 550.71 | 852.47 | 2,302.64 | 2,677.71 | |
| 2 | Expenses | |||||
| a) Cost of materials consumed | 138.96 | 196.50 | 202.23 | 705.39 | 710.06 | |
| b) Changes in inventories of finished goods and work-in-progress | 75.49 | (37.59) | 97.79 | (42.76) | 106.42 | |
| c) Employee benefits expense | 128.99 | 118.68 | 138.53 | 507.71 | 447.81 | |
| d) Finance costs | 9.19 | 9.11 | 10.45 | 37.24 | 41.06 | |
| e) Depreciation and amortisation expenses | 51.23 | 46.94 | 54.17 | 187.33 | 166.80 | |
| f) Other expenses | 177.00 | 171.61 | 172.65 | 671.22 | 547.15 | |
| Total expenses | 580.86 | 505.25 | 675.82 | 2,066.13 | 2,019.30 | |
| 3 | Profit before tax and exceptional items (1-2) | 36.42 | 45.46 | 176.65 | 236.51 | 658.41 |
| 4 | Exceptional items (refer note 6) | 16.51 | 4.86 | 15.78 | 29.47 | 15.78 |
| 5 | Profit before tax and share of associate (3-4) | 19.91 | 40.60 | 160.87 | 207.04 | 642.63 |
| 6 | Tax expenses | |||||
| a) Current tax | 17.55 | 12.43 | 34.21 | 75.20 | 168.02 | |
| b) Current tax – earlier years | 4.69 | (2.31) | 4.69 | 4.26 | ||
| c) Deferred tax | (10.64) | (0.85) | 11.82 | (22.97) | (13.89) | |
| Total tax expense (net) | 11.60 | 11.58 | 43.72 | 56.92 | 158.39 | |
| 7 | Net profit after tax before share of associate (5-6) | 8.31 | 29.02 | 117.15 | 150.12 | 484.24 |
| 8 | Share of profit/(loss) of Associate | |||||
| 9 | Net profit for the period/year (7-8) | 8.31 | 29.02 | 117.15 | 150.12 | 484.24 |
| 10 | Net profit/(loss) for the period/year attributable to | |||||
| a) Shareholders of the company | 19.55 | 36.72 | 120.43 | 179.23 | 487.34 | |
| b) Non-controlling interest | (11.24) | (7.70) | (3.28) | (29.11) | (3.10) | |
| 11 | Other comprehensive income | |||||
| 11.a | Items that will not be reclassified to profit or loss | |||||
| (i) Gain / (loss) on remeasurement of defined benefit plan | 2.28 | (0.21) | 0.34 | 2.13 | 0.14 | |
| (ii) Change in the fair value of equity instrument classified at FVOCI | 94.65 | 8.44 | 94.65 | 8.44 | ||
| (iii) Income tax relating to items that will not be reclassified to profit or loss | (26.60) | 0.06 | (2.54) | (26.56) | (2.49) | |
| 11.b | Items that will be reclassified to profit or loss | |||||
| (i) Effective portion of gain / (loss) on hedging instrument in a cash flow hedging | (5.54) | 4.25 | (9.93) | |||
| (ii) Exchange differences on Translating foreign operations | 19.88 | 4.01 | 3.40 | 36.25 | 6.81 | |
| (iii) Income tax relating to items that will be reclassified to profit or loss | 1.40 | (1.08) | 2.50 | |||
| Total other comprehensive income for the period/year | 86.07 | 7.03 | 9.64 | 99.04 | 12.90 | |
| 12 | Total comprehensive income for the period/year (9+11) | 94.38 | 36.05 | 126.79 | 249.16 | 497.14 |
| 13 | Total comprehensive income/(loss) for the period/year attributable to | |||||
| a) Shareholders of the company | 101.91 | 42.86 | 129.47 | 270.68 | 499.64 | |
| b) Non-controlling interest | (7.53) | (6.81) | (2.68) | (21.52) | (2.50) | |
| 14 | Paid-up equity share capital (refer note 4) | 38.26 | 38.26 | 25.46 | 38.26 | 25.46 |
| Face value of the share | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 | |
| 15 | Other equity | 3,873.03 | 3,623.36 | |||
| 16 | Earning Per Share (EPS)- (Face value of ₹1/- each) (refer note 8) | |||||
| a) Basic | 0.51 | 0.96 | 3.16 | 4.69 | 12.79 | |
| b) Diluted | 0.50 | 0.96 | 3.10 | 4.68 | 12.68 |
| Particulars | Standalone as at 31-Mar-26 Audited | Standalone as at 31-Mar-25 Audited Restated (refer note 4) | Consolidated as at 31-Mar-26 Audited | Consolidated as at 31-Mar-25 Audited Restated (refer note 4) |
|---|---|---|---|---|
| A ASSETS | ||||
| 1 Non-current assets | ||||
| (a) Property, plant and equipment | 1,545.66 | 1,322.73 | 1,759.01 | 1,523.00 |
| (b) Right of use of assets | 62.13 | 70.31 | 231.07 | 241.80 |
| (c) Capital work-in-progress | 144.06 | 329.93 | 173.22 | 331.60 |
| (d) Goodwill | 644.11 | 644.11 | 1,283.65 | 1,238.96 |
| (e) Other intangible assets | 35.98 | 41.51 | 95.01 | 103.53 |
| (f) Intangible assets under development | 1.74 | 2.82 | 4.51 | 2.82 |
| (g) Financial assets |